Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Mirum Pharmaceuticals (MIRM) Change in Accured Expenses (2020 - 2025)

Mirum Pharmaceuticals (MIRM) has 6 years of Change in Accured Expenses data on record, last reported at $3.4 million in Q4 2025.

  • For Q4 2025, Change in Accured Expenses fell 63.13% year-over-year to $3.4 million; the TTM value through Dec 2025 reached $50.1 million, up 24.29%, while the annual FY2025 figure was $50.1 million, 24.29% up from the prior year.
  • Change in Accured Expenses reached $3.4 million in Q4 2025 per MIRM's latest filing, down from $24.3 million in the prior quarter.
  • Across five years, Change in Accured Expenses topped out at $24.3 million in Q3 2025 and bottomed at -$8.1 million in Q1 2022.
  • Average Change in Accured Expenses over 5 years is $7.6 million, with a median of $9.1 million recorded in 2021.
  • Peak YoY movement for Change in Accured Expenses: plummeted 344.92% in 2021, then surged 250660.0% in 2023.
  • A 5-year view of Change in Accured Expenses shows it stood at $9.0 million in 2021, then crashed by 100.06% to -$5000.0 in 2022, then soared by 250660.0% to $12.5 million in 2023, then dropped by 25.45% to $9.3 million in 2024, then tumbled by 63.13% to $3.4 million in 2025.
  • Per Business Quant database, its latest 3 readings for Change in Accured Expenses were $3.4 million in Q4 2025, $24.3 million in Q3 2025, and $10.6 million in Q2 2025.